Evidence map›Paper›PMID 40612721›Full record

ArticleIranian journal of microbiology2025

Evaluation of the prevention, treatment and synergistic activity between

Sara Kamal Shahsavar, Zahra Esmaeili, Hamid Ariannejad, Mohammadreza Nassiri, Ali Beheshti Namdar, Amir Hossein Jafarian, Ramin Sadeghi, Vahid Reza Dabbagh, Kiarash Ghazvini

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Iranian journal of microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Efficacy of IgY onAntibody therapeutics · 2026
    Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Sara Kamal ShahsavarDepartment of Microbiology and Virology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Zahra EsmaeiliDepartment of Microbiology and Virology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Hamid AriannejadDepartment of Animal Sciences, School of Agriculture, Ferdowsi University, Mashhad, Iran.
Mohammadreza NassiriDepartment of Animal Sciences, School of Agriculture, Ferdowsi University, Mashhad, Iran.
Ali Beheshti NamdarDepartment of Gastroenterology and Hepatology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Amir Hossein JafarianDepartment of Pathology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Ramin SadeghiDepartment of Nuclear Medicine, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Vahid Reza DabbaghDepartment of Nuclear Medicine, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Kiarash GhazviniDepartment of Microbiology and Virology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and Objectives: The growing resistance of Materials and Methods: This investigation specifically focused on the inhibitory effects of IgY in the AGS cell line infected with Results: The findings indicated that IgY antibodies possess a substantial inhibitory effect on the adhesion of Conclusion: The use of IgY has the potential to repair damaged cells and prevent infection by decreasing bacterial adherence to gastric epithelial cells. Given its synergistic effect with pantoprazole, IgY can be recommended as a suitable complementary treatment in conjunction with pantoprazole.

Indexed as

C57BL MiceCell lineGastrointestinal diseasesHelicobacter pyloriImmunoglobulin YTherapeutic

Identifiers

PMID40612721
PMCPMC12218885

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.